Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease

NCT01689233 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

800

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer's Disease

Interventions

DRUG: TRx0237 200 mg/day
DRUG: Placebo

Sponsor

TauRx Therapeutics Ltd